S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
Log in

NASDAQ:ZFGN - Zafgen Stock Price, Forecast & News

$1.22
-0.07 (-5.43 %)
(As of 01/17/2020 04:00 PM ET)
Today's Range
$1.16
Now: $1.22
$1.30
50-Day Range
$0.71
MA: $1.00
$1.48
52-Week Range
$0.62
Now: $1.22
$5.45
Volume138,513 shs
Average Volume458,343 shs
Market Capitalization$45.60 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.38
Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ZFGN
CUSIPN/A
Phone617-622-4003

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.53 per share

Profitability

Net Income$-61,370,000.00

Miscellaneous

Employees38
Market Cap$45.60 million
Next Earnings Date3/9/2020 (Estimated)
OptionableOptionable

Receive ZFGN News and Ratings via Email

Sign-up to receive the latest news and ratings for ZFGN and its competitors with MarketBeat's FREE daily newsletter.


Zafgen (NASDAQ:ZFGN) Frequently Asked Questions

What is Zafgen's stock symbol?

Zafgen trades on the NASDAQ under the ticker symbol "ZFGN."

How were Zafgen's earnings last quarter?

Zafgen Inc (NASDAQ:ZFGN) issued its earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.27) by $0.03. View Zafgen's Earnings History.

When is Zafgen's next earnings date?

Zafgen is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Zafgen.

What price target have analysts set for ZFGN?

7 equities research analysts have issued twelve-month price objectives for Zafgen's stock. Their forecasts range from $0.78 to $17.00. On average, they anticipate Zafgen's stock price to reach $7.06 in the next twelve months. This suggests a possible upside of 478.7% from the stock's current price. View Analyst Price Targets for Zafgen.

What is the consensus analysts' recommendation for Zafgen?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zafgen in the last year. There are currently 5 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Zafgen.

Has Zafgen been receiving favorable news coverage?

Headlines about ZFGN stock have trended somewhat positive on Friday, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Zafgen earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Zafgen.

Are investors shorting Zafgen?

Zafgen saw a decrease in short interest in December. As of December 31st, there was short interest totalling 520,800 shares, a decrease of 9.8% from the December 15th total of 577,500 shares. Based on an average trading volume of 687,800 shares, the short-interest ratio is presently 0.8 days. Currently, 1.6% of the shares of the stock are sold short. View Zafgen's Current Options Chain.

Who are some of Zafgen's key competitors?

What other stocks do shareholders of Zafgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zafgen investors own include CA (CA), Endologix (ELGX), TG Therapeutics (TGTX), BlackRock (BLK), Micron Technology (MU), Energy Transfer LP Unit (ET), Fate Therapeutics (FATE), SCYNEXIS (SCYX), Esperion Therapeutics (ESPR) and Lexicon Pharmaceuticals (LXRX).

Who are Zafgen's key executives?

Zafgen's management team includes the folowing people:
  • Mr. Jeffrey S. Hatfield, CEO & Director (Age 61)
  • Ms. Patricia L. Allen, Chief Financial Officer (Age 57)
  • Dr. Dennis D. Kim M.D., MBA, Chief Medical Officer (Age 49)
  • Dr. James E. Vath, Head of Discovery & Devel. (Age 58)
  • Mr. Brian P. McVeigh, Chief Bus. Officer (Age 46)

Who are Zafgen's major shareholders?

Zafgen's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Wedbush Securities Inc. (0.23%). View Institutional Ownership Trends for Zafgen.

Which major investors are selling Zafgen stock?

ZFGN stock was sold by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. View Insider Buying and Selling for Zafgen.

How do I buy shares of Zafgen?

Shares of ZFGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Zafgen's stock price today?

One share of ZFGN stock can currently be purchased for approximately $1.22.

How big of a company is Zafgen?

Zafgen has a market capitalization of $45.60 million. The biopharmaceutical company earns $-61,370,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis. Zafgen employs 38 workers across the globe.View Additional Information About Zafgen.

What is Zafgen's official website?

The official website for Zafgen is http://www.zafgen.com/.

How can I contact Zafgen?

Zafgen's mailing address is 3 Center Plaza Suite 610, BOSTON MA, 02108. The biopharmaceutical company can be reached via phone at 617-622-4003 or via email at [email protected]


MarketBeat Community Rating for Zafgen (NASDAQ ZFGN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  333 (Vote Outperform)
Underperform Votes:  305 (Vote Underperform)
Total Votes:  638
MarketBeat's community ratings are surveys of what our community members think about Zafgen and other stocks. Vote "Outperform" if you believe ZFGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZFGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2020 by MarketBeat.com Staff

Featured Article: Bid-Ask Spread

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel